Hubungan Antara Ekspresi LMP1 dan Karakteristik Klinikopatologis Karsinoma Payudara Invasif Di RSUP Dr. Kariadi Semarang

Ika Pawitra Miranti(1*), Dik Puspasari(2), Hermawan Istiadi(3), Vega Karlowee(4)


(1) Universitas Diponegoro-RSUP dr Kariadi Semarang.
(2) Universitas Diponegoro-RSUP dr Kariadi Semarang.
(3) Universitas Diponegoro-RSUP dr Kariadi Semarang.
(4) Universitas Diponegoro-RSUP dr Kariadi Semarang.
(*) Corresponding Author

Abstract


Latar Belakang: Sekitar 30-50% karsinoma payudara positif terhadap virus Epstein-Barr (EBV). Studi melaporkan bahwa karsinoma payudara positif EBV cenderung lebih agresif. Infeksi EBV dapat dibuktikan salah satunya melalui pemeriksaan LMP1. Sejauh ini studi tentang infeksi EBV terhadap karakteristik klinikopatologis karsinoma payudara di negara-negara Asia termasuk Indonesia masih terbatas. Penelitian ini bertujuan menganalisis hubungan ekspresi LMP1 dengan karakteristik klinikopatologis karsinoma payudara invasif.

Metode: Penelitian cross-sectional menggunakan 64 sampel blok parafin dari pasien karsinoma payudara invasif di RSUP Dr. Kariadi periode Juni-September 2019. Ekspresi LMP1 dinilai dengan immunostaining. Data klinikopatologis berupa usia, ukuran tumor, grade, ekspresi ER, PR, HER2, Ki67, subtipe molekuler dan keterlibatan KGB aksila. Analisis menggunakan uji korelasi dan SPSS 17.

Hasil: Dari 64 kasus karsinoma payudara invasif, sebagian besar berusia >50 tahun (59,4%), ukuran T2 (45,3%), grade 2 (70,3%), ekspresi ER positif (62,5%), ekspresi PR negatif (56,3%), ekspresi HER2 negatif (64,1%), indeks Ki67 > 20% (75%), subtipe molekuler Luminal B-like (HER2 negative) (31,3%) dan metastasis KGB N1 (35,9%). Ekspresi hanya berkorelasi dengan metastasis KGB (p=0.01), bermakna karsinoma payudara invasif dengan LMP1 positif menunjukkan semakin tinggi risiko keterlibatan KGB.

Kesimpulan: Ekspresi LMP1 berkorelasi dengan tingkat metastasis KGB.


Keywords


Karsinoma payudara invasif, LMP1, karakteristik klinikopatologis

Full Text:

PDF

References


Rokom. Kanker payudara paling ba-nyak di indonesia, kemenkes targetkan pemerataan layanan kesehatan [Internet]. Kemkes: Sehat Negeriku. 2022. Available from: https://sehatnegeriku.kemkes.go. id/baca/umum/20220202/1639254/kanker-payudaya-paling-banyak-di-indo nesia-kemenkes-targetkan-pemerataan -layanan-kesehatan/

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71 (3):209–49.

Zhang X. Classification of breast cancer: relevance and challenges. Arch Pathol Lab Med. 2023;147:46–51.

Goldblum JR, Lamps LW, McKenney JK. Rosai and ackerman’s surgical pa-thology. Philadelohia: Elsevier Inc.; 2017.

International Agency for Research on Cancer. WHO classification of tumours: Breast tumours. W. H. O. Classification WHO Classification of Tumours Edi-torial Board, editor. World Health Or-ganization; 2019.

Ahmed ES, Elnour LS, Siddig EE, Hassan R. Molecular detection of Eps-tein-Barr virus in breast cancer among Sudanese female population: a case-control study. F1000Research. 2019;8 :1355.

Shahi V, Agarwal P, Qayoom S, Kumar V, Tewari S, Raghuvanshi S, et al. Detection of epstein barr nuclear antigen-1 (EBNA-1), early antigen 1F, 2R (EA-1F, EA-2R) along with epstein–barr virus latent membrane protein 1 (LMP1) in Breast cancer of northern india: An interim analysis. Asian Pacific J Cancer Prev. 2022;23(11): 3717–23.

Shechter O, Sausen DG, Gallo ES, Dahari H, Borenstein R. Epstein–barr virus (EBV) epithelial associated malig-nancies: Exploring pathologies and current treatments. Int J Mol Sci. 2022; 23(14389):1–22.

Möhl BS, Chen J, Sathiyamoorthy K, Jardetzky TS, Longnecker R. Structural and mechanistic insights into the tropism of epstein-barr virus. Mol Cells. 2016;39(4):286–91.

Zekri ARN, Bahnassy AA, Mohamed WS, El-Kassem FA, El-Khalidi SJ, Hafez MM, et al. Epstein-barr virus and breast cancer: Epidemiological and molecular study on egyptian and iraqi women. J Egypt Natl Canc Inst. 2012; 24(3):123–31.

Rutherford SC, Leonard JP. DLBCL cell of origin: What role should it play in care today? Oncol (United States). 2018;32(9):445–9.

Ćojbašić I, Mačukanović-Golubović L. Analysis of prognostic factors in Hod-gkin’s lymphoma with regard to response to treatment. FACTA Univ. 2007;14(3): 117–20.

Gupta I, Ulamec M, Peric-balja M, Ramic S. Presence of high-risk HPVs , EBV, and MMTV in human triple-negative breast cancer. Hum Vaccin Immunother. 2021;17(11):4457–66.

Zhang W tong, Zhu G lu, Xu W qin, Zhang W, Wang H zhen, Wang Y bing, et al. Association of PD-1/PD-L1 expression and Epstein-–Barr virus infection in patients with invasive breast cancer. Diagn Pathol. 2022;17 (1):1–11.

Nagi K, Gupta I, Jurdi N, Jabeen A, Yasmeen A, Batist G, et al. High-risk human papillomaviruses and Epstein–Barr virus in breast cancer in Lebanese women and their association with tumor grade: a molecular and tissue microarray study. Cancer Cell Int. 2021;21(308): 1–10.

Cyprian FS, Al-antary N, Moustafa A eddin Al. HER-2/ Epstein-Barr virus crosstalk in human gastric carcino-genesis : A novel concept of oncogene/ oncovirus interaction. Cell Adhes Migr. 2018;12(1):1–4.

Lo AKF, Dawson CW, Lung HL, Wong KL, Young LS. The Role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: From Function to Therapy. Front Oncol. 2021;11:1–17.


Article Metrics

Abstract view : 135 times
PDF - 15 times

DOI: https://doi.org/10.26714/medart.6.1.2024.1-9

Refbacks

  • There are currently no refbacks.


Contact

Faculty of Medicine, Universitas Muhammadiyah Semarang
Jl. Kedungmundu Raya No. 18, Semarang, Indonesia
Email: [email protected]